Dianthus Therapeutics to Host Conference Call and Webcast to Discuss the Interim Responder Analysis Results of the Phase 3 Captivate Trial of Claseprubart in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
· dianthus therapeutics, inc.
AI Briefing
- Dianthus Therapeutics to discuss interim responder analysis results from Phase 3 CAPTIVATE trial of claseprubart in CIDP.
- Conference call and webcast set for March 9, 2026 at 8:00 a.m. ET.
- Company dedicated to developing next-generation therapies for severe autoimmune diseases.
Advertisement